Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01227382 · ClinicalTrials.gov registry record · NA
Accuracy of Spybite Forceps When Compared to Conventional Sampling Methods
A NA study of Pancreatic Duct Stricture and Accuracy of Tissue Diagnosis, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT01227382: Completed NA study of Pancreatic Duct Stricture and Accuracy of Tissue Diagnosis, sponsored by University of Florida.
NCT01227382 is a NA study of Pancreatic Duct Stricture and Accuracy of Tissue Diagnosis that has completed, run by University of Florida. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01227382, a NA study of Pancreatic Duct Stricture and Accuracy of Tissue Diagnosis, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are evaluating the use of a SpyBite biopsy forceps for tissue diagnosis when compared to standard biopsy techniques.
Primary Outcome
The diagnostic accuracy of the Spybite Biopsy forceps was compared to both the cytology brush and the RJ3 biopsy forceps sampling of any stricture or biliary lesions found on Endoscopic Retrograde Cholangiopancreatography (ERCP). All three methods were used at baseline to obtain a sample for the determination of cancer vs. no cancer.
Conditions Studied
Interventions
- PROCEDURE ERCP with cholangiopancreatoscopy
Study Locations (1)
Florida
- Shands at UF Ensopcopy - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2006-11 |
| Est. Completion | 2015-05 |
| Phase | NA |
What the finished NCT01227382 record still lists
NCT01227382 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Pancreatic Duct Stricture appearing as the primary indexed condition, and to 1 intervention - of which ERCP with cholangiopancreatoscopy is the first listed.
NCT01227382 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT01227382 about?
NCT01227382 is a clinical study titled "Accuracy of Spybite Forceps When Compared to Conventional Sampling Methods". The investigators are evaluating the use of a SpyBite biopsy forceps for tissue diagnosis when compared to standard biopsy techniques.
What is the current status of trial NCT01227382?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2006-11. Estimated completion is 2015-05.
What conditions does trial NCT01227382 study?
This clinical trial studies the following conditions: Pancreatic Duct Stricture, Accuracy of Tissue Diagnosis, Bile Duct Stricture.
What interventions are being tested in trial NCT01227382?
The interventions under investigation include: ERCP with cholangiopancreatoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT01227382?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01227382 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Duct Stricture
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01227382's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia